Fig. 14From: Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer modelImpact of protein dose blood to spleen activity concentration ratio at 6 h post-injection of 111In-anti-PD-L1-BCBack to article page